🏛️ Verified NIH Record • Updated 2021-07-19
Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach (NCT04022109)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: University of Latvia
🩺 Plain-English Summary (8th-Grade Level)
The study is aimed to determine the potential of volatile marker testing for gastric cancer screening. The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.
Who can join: Review the eligibility criteria below.
Location: A.C.Camargo Cancer Center — São Paulo
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- A.C.Camargo Cancer Center — São Paulo,
- Pontificia Universidad Catolica de Chile — Santiago,
- Centro Javeriano de Oncología, San Ignacio University Hospital — Bogotá,
- Institute of Clinical and Preventive Medicine, University of Latvia — Riga,
- National Cancer Institute of Ukraine — Kiev,
📞 Contact the Study Coordinator
Phone: +37129497500
Email: marcis.leja@lu.lv
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastric Cancer
- A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Scottsdale, Arizona
- Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer — Los Angeles, California
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) — Baltimore, Maryland
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer — Baltimore, Maryland
- Study for AZD4360 in Participants With Advanced Solid Tumours — Santa Monica, California
- Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma — Tampa, Florida
Explore by condition: All Gastric Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.